Table 4

Therapy outcome of ICI

Total patient population (N=835)Patients with brain metastases
(N=223)
Anti-CTLA-4 (n=596)Anti-PD-1 (n=239)Anti-CTLA-4 (n=160)/anti-PD-1 (n=63)
No preceding RTPreceding RTNo preceding RTPreceding RTNo preceding RTPreceding RT
n%n%n%n%n%n%
Total4461001501001541008510086100137100
Best overall response
 CR163.621.363.922.40010.7
 PR429.4117.33321.41214.133.5118.0
 SD5913.21812.02415.62327.6910.52216.0
 PD30568.411073.37951.34148.27081.49569.4
 Missing data245.496.0127.878.244.685.9
Objective response
 Responders (CR/PR)5813.0138.73925.31416.533.5128.8
 Non-responders (SD/PD)36481.612885.310366.96475.37991.911785.4
 Missing data245.496.0127.878.344.785.9
 RR (95% CI); p value1.47 (0.81 to 2.65); p=0.200.93 (0.49 to 1.77); p=0.862.54 (0.73 to 8.75); p=0.14
PFS
 Median (months)
 (95% CI)
3.1
(2.0 to 5.9)
2.8
(1.5 to 4.6)
4.2
(2.3 to 17.3)
4.0
(2.4 to 8.2)
2.7
(1.4 to 3.5)
2.8
(1.5 to 5.1)
 HR (95% CI); p value1.02 (0.86 to 1.25); p=0.740.84 (0.57 to 1.26); p=0.410.85 (0.63 to 1.15); p=0.29
OS
 Median (months)
 (95% CI)
9.6
(4.2 to 21.3)
6.8
(3.3 to 15.7)
17.5
(4.6 to 34.3)
10.8
(5.2 to NR)
4.6
(2.4 to 9.8)
6.4
(2.7 to 14.8)
 HR (95% CI); p value1.08 (0.81 to 1.44); p=0.610.73 (0.43 to 1.25); p=0.260.77 (0.53 to 1.13); p=0.18
  • Therapy outcome of CI is shown separately for patients treated with anti-CTLA-4 and for patients treated with anti-PD-1, as well as for a subgroup of patients with brain metastases (M1d) treated with either anti-CTLA-4 or anti-PD-1. The effect of a preceding radiotherapy on response to ICI is given as RR to achieve an objective response; the effect of a preceding radiotherapy on survival on ICI therapy is given as HR to attain a progression (PFS) or death (OS). All RR, HR, and p values result from multivariable analyses adjusted for confounders.

  • ICI, immune checkpoint inhibition; NR, not reached; OS, overall survival; PFS, progression-free survival; RR, relative risk.